Orive G, Bartkowiak A, Lisiecki S, De Castro M, Hernández R M, Gascòn A R, Pedraz J L
Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria -Gasteiz. Spain.
J Biomed Mater Res B Appl Biomater. 2005 Jul;74(1):429-39. doi: 10.1002/jbm.b.30146.
In the past, it has been proven that by properly adjusting the molecular mass of the oligochitosan samples, it is possible to optimize the formation of rigid, biocompatible capsules with semipermeable membranes under physiological conditions. In this study, the feasibility of four oligochitosan samples, with varying molar masses (M(n) in range 3-5 kDa), as biocompatible coatings of alginate/Ca capsules was investigated. By selection of appropriate depolymerization and purification methods we obtained oligochitosan samples that appeared to be noncytotoxic for C(2)C(12) myoblasts and did not influence the mammalian cell metabolism especially in relative short time during the process of capsule formation. Furthermore, oligochitosans can be used as a tool to reduce the membrane cut-off of the alginate capsules. However, such reduction, as well as mechanical resistance of formed microcapsules, depend on MM of the cationic polysaccharide and the chemical composition of the alginate (mannuronic/guluronic acid ratio). Here, we address that the use of low molar mass chitosan (< 5000 g/mol) permits the formation of mechanical stable capsules at physiological pH, which represents a strong advantage over other chitosan-based chemistries.
过去已经证明，通过适当调整低聚壳聚糖样品的分子量，在生理条件下优化具有半透膜的刚性、生物相容性胶囊的形成是可能的。在本研究中，研究了四种不同摩尔质量（M(n)范围为3-5 kDa）的低聚壳聚糖样品作为藻酸盐/Ca胶囊生物相容性涂层的可行性。通过选择合适的解聚和纯化方法，我们获得了对C(2)C(12)成肌细胞无细胞毒性且在胶囊形成过程中相对短时间内不影响哺乳动物细胞代谢的低聚壳聚糖样品。此外，低聚壳聚糖可用作降低藻酸盐胶囊膜截留率的工具。然而，这种降低以及形成的微胶囊的机械抗性取决于阳离子多糖的分子量和藻酸盐的化学组成（甘露糖醛酸/古洛糖醛酸比率）。在此，我们指出使用低摩尔质量壳聚糖（<5000 g/mol）允许在生理pH下形成机械稳定的胶囊，这相对于其他基于壳聚糖的化学方法具有很大优势。
